IPOs & Offerings

Moleculin files preliminary registration statement for best-efforts securities offering

The biotechnology company’s preliminary prospectus describes an offering of common stock or pre-funded warrants with accompanying common warrants, subject to the registration statement becoming effective.

By Carter Hayes · August 4, 2026

Preliminary prospectus describes proposed offering

Moleculin Biotech’s Form S-1 includes a preliminary prospectus for a proposed public offering. The filing states that the prospectus is incomplete and may change, and that securities may not be sold until the registration statement is effective.

The proposed transaction is structured as a reasonable-best-efforts offering. Roth Capital Partners is named as the exclusive placement agent, but it is not required to arrange the purchase or sale of a specified number or dollar amount of securities.

The offering includes common stock and an alternative of pre-funded warrants for certain purchasers. Common warrants would accompany each share of common stock or pre-funded warrant sold in the offering.

Terms include no minimum funding condition

The filing states that there is no minimum number of securities to be sold and no minimum aggregate proceeds required for the offering to close. It also says there is no arrangement for offering funds to be held in escrow, trust or a similar arrangement.

Moleculin may sell fewer than all securities included in the preliminary prospectus. The company says this could significantly reduce the proceeds it receives.

The preliminary prospectus states that the offering is scheduled to terminate by August 14, 2026, unless Moleculin chooses to end it earlier.

Company identifies intended use of proceeds

Moleculin says it intends to use net proceeds from the offering to advance Annamycin through clinical development and for working capital.

The filing describes Annamycin as the company’s lead drug candidate and states that Moleculin is conducting the MIRACLE Phase 2/3 trial involving relapsed or refractory acute myeloid leukemia.

Moleculin also states that it will require significant additional financing, for which it currently has no commitments, to continue funding its clinical trials, including MIRACLE.

Warrants would not have an established trading market

The company states that there is no established public trading market for the pre-funded warrants or common warrants and that it does not expect one to develop.

Moleculin does not intend to apply to list the pre-funded warrants or common warrants on a securities exchange or other nationally recognized trading system.

Its common stock is listed on the Nasdaq Capital Market under the symbol MBRX, according to the prospectus.